cancer care engineering colorectal cancer gabriela chiorean, m.d. may 27, 2011

Cancer Care Engineering Colorectal Cancer

Gabriela Chiorean, M.D.

May 27, 2011

Rationale

Perform OMICs of healthy, polyps, cancer

Compare OMICs between cancer, polyps and healthy: develop new screening and risk assessment tools

Analyse changes in OMICs with treatment and correlate with response/toxicity: predictive markers

Schema IUCRO-0221CCE in CRC

SAMPLES

Blood (Serum)7 mL red top

Metabolomics, vit D

Blood (Plasma)21 mL purple top

Genomics, lipidomics, glycoproteomics

N=810

Stratification:- Healthy

(n=270)- Polyps

(n=270)- Cancer

(n=270)

stg 1/2

stg 3

stg 4 metastatic

Fresh Tissue10 mg polyp or50 mg cancer /

50 mg normal tissue

SHIP

DRY

ICE

8-hr fasting

Paraffin-Embedded TissueMSI, methylation, KRAS, BRAF, p53

Samples Collection Healthy Controls

Screening Colonoscopy – GI Clinic

Label specimensHealthy

if no polyps/tumor

Blood Questionnaires

N= 5 6/2009N=74 5/2010N=109 5/2011

Samples Collection Adenomatous Polyps

Screening Colonoscopy – GI Clinic

Label specimensPolyp

Polyps identified

Tissue procurement/Research specialist -Polyp cut in ½

-Place in tube with no preservative-Freeze at -70oC

Blood Questionnaires

N= 3 6/2009N= 65 5/2010N= 96 5/2011

Samples Collection Cancer

Surgery

Tissue:tumor, normal mucosa

Blood Questionnaires

Chemotherapy Follow-up

Every 3 months Up to 24 months

N= 8 6/2009 N= 34 5/2010N= 55 5/2011

Sample Acquisition4/2009-5/2011

Cancer total No prior chemo Prior chemo

n=55 n=26 n=29 Stage 1 n=6 n=6 0Stage 2 n=3 n=2 n=1Stage 3 n=17 n=10

n=7Stage 4 n=29 n=8 n=21